These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7456197)

  • 1. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy.
    Klugo RC; Farah RN; Cerny JC
    Urology; 1981 Jan; 17(1):49-50. PubMed ID: 7456197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
    Lin BJ; Chen KK; Chen MT; Chang LS
    Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.
    Geller J; Albert JD; Nachtsheim DA; Loza D
    J Urol; 1984 Oct; 132(4):693-6. PubMed ID: 6471215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment testosterone levels: significance in androgen deprivation therapy.
    Hickey D; Todd B; Soloway MS
    J Urol; 1986 Nov; 136(5):1038-40. PubMed ID: 3095566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
    Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
    Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma androgen levels after subcapsular orchiectomy or estrogen treatment for prostatic carcinoma.
    Vermeulen A; Schelfhout W; De Sy W
    Prostate; 1982; 3(2):115-21. PubMed ID: 6211662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic prostate cancer. Factors that influence treatment selection and methods to increase acceptance of orchiectomy.
    Merrill DC
    Urology; 1988 Nov; 32(5):408-12. PubMed ID: 3188303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view.
    Bishop MC
    Br J Urol; 1996 Dec; 78(6):921-7; discussion 927-8. PubMed ID: 9014720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Koontz WW; Prout GR
    Invest Urol; 1972 Mar; 9(5):423-5. PubMed ID: 5016026
    [No Abstract]   [Full Text] [Related]  

  • 18. Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma.
    Tomić R
    J Endocrinol Invest; 1987 Oct; 10(5):479-82. PubMed ID: 3123547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
    Tomić R; Damber JE
    Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.
    Tomić R; Bergman B
    J Urol; 1987 Oct; 138(4):801-3. PubMed ID: 3116281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.